Page last updated: 2024-09-03

ginsenoside rh2 and docetaxel anhydrous

ginsenoside rh2 has been researched along with docetaxel anhydrous in 2 studies

Compound Research Comparison

Studies (ginsenoside rh2)	Trials (ginsenoside rh2)	Recent Studies (post-2010) (ginsenoside rh2)	Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)
295	1	200	12,110	3,216	6,920

Protein Interaction Comparison

Protein	Taxonomy	ginsenoside rh2 (IC50)	docetaxel anhydrous (IC50)
Kinesin-like protein KIF11	Homo sapiens (human)		0.0014
Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)		5.0119

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adomat, H; Bally, MB; Eberding, A; Fazli, L; Guns, ET; Hurtado-Coll, A; Jia, W; Musende, AG; Wood, C	1
Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E	1

Other Studies

2 other study(ies) available for ginsenoside rh2 and docetaxel anhydrous

Article	Year
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6 Topics: Administration, Oral; Alanine Transaminase; Animal Structures; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aspartate Aminotransferases; Body Weight; Cell Line, Tumor; Creatinine; Docetaxel; Drug Stability; Ginsenosides; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Prostatic Neoplasms; Solubility; Solvents; Taxoids; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays	2009
Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. The Prostate, 2010, Sep-15, Volume: 70, Issue:13 Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids	2010

Article

Year

Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.

Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6

Topics: Administration, Oral; Alanine Transaminase; Animal Structures; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aspartate Aminotransferases; Body Weight; Cell Line, Tumor; Creatinine; Docetaxel; Drug Stability; Ginsenosides; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Prostatic Neoplasms; Solubility; Solvents; Taxoids; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays

2009

Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.

The Prostate, 2010, Sep-15, Volume: 70, Issue:13

Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids

2010